Literature DB >> 25801474

Needs Assessment and Theory-Based Promotion of Voluntary Medical Male Circumcision (VMMC) Among Male Sexually Transmitted Diseases Patients (MSTDP) in China.

Zixin Wang1,2, Tiejian Feng3, Joseph T F Lau4,5,6,7.   

Abstract

Voluntary medical male circumcision (VMMC) is an evidence-based biomedical HIV prevention method. It is under-utilized in countries outside Africa, including China. The present single-arm, non-blinded test-of-concept trial was designed to promote VMMC among 179 male sexually transmitted diseases patients (MSTDP) in Shenzhen, China. It was based on behavioral health theories and results of a formative survey. At month 4, 45.5 % of the MSTDP responded positively to the intervention (19.9 % had taken up VMMC and 25.6 % intended to do so in the next 6 months). Adjusted analysis showed that cognitive variables measured at baseline (perceived self-efficacy, subjective norm and behavioral intention) significantly predicted adoption of VMMC during the 4-month follow-up period. Process evaluation involving clinicians of the STD clinics was positive. At month 6, 36.0 % of the circumcised participants used condom less frequently with their regular sex partner. We recommend scaling up the intervention, taking prevention of risk compensation into account.

Entities:  

Keywords:  China; Male STD patients; Promotion; Risk compensation; Voluntary medical male circumcision

Mesh:

Year:  2016        PMID: 25801474     DOI: 10.1007/s10461-015-1040-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  2 in total

1.  Acceptability of Voluntary Medical Male Circumcision (VMMC) among Male Sexually Transmitted Diseases Patients (MSTDP) in China.

Authors:  Zixin Wang; Tiejian Feng; Joseph T F Lau; Yoona Kim
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

2.  Uptake of voluntary medical male circumcision among men with sexually transmitted infections in Lilongwe, Malawi: a protocol for a pre-interventional and post-interventional study.

Authors:  Mitch M Matoga; Mina C Hosseinipour; Sara Jewett; Charles Chasela
Journal:  BMJ Open       Date:  2022-01-18       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.